Cullinan Oncology logo

Cullinan OncologyNASDAQ: CGEM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 January 2021

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$732.50 M
-56%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:26:22 GMT
$12.58-$0.52(-3.97%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CGEM Latest News

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
globenewswire.com05 November 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
globenewswire.com14 September 2024 Sentiment: POSITIVE

Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
globenewswire.com23 May 2024 Sentiment: POSITIVE

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire18 December 2023 Sentiment: POSITIVE

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).

Why Shares of Cullinan Oncology Jumped This Week
The Motley Fool09 June 2023 Sentiment: POSITIVE

Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and published encouraging news regarding preclinical candidate CLN-619 as a pan-cancer treatment.

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
GlobeNewsWire26 April 2023 Sentiment: NEGATIVE

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.

What type of business is Cullinan Oncology?

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

What sector is Cullinan Oncology in?

Cullinan Oncology is in the Healthcare sector

What industry is Cullinan Oncology in?

Cullinan Oncology is in the Biotechnology industry

What country is Cullinan Oncology from?

Cullinan Oncology is headquartered in United States

When did Cullinan Oncology go public?

Cullinan Oncology initial public offering (IPO) was on 08 January 2021

What is Cullinan Oncology website?

https://cullinantherapeutics.com

Is Cullinan Oncology in the S&P 500?

No, Cullinan Oncology is not included in the S&P 500 index

Is Cullinan Oncology in the NASDAQ 100?

No, Cullinan Oncology is not included in the NASDAQ 100 index

Is Cullinan Oncology in the Dow Jones?

No, Cullinan Oncology is not included in the Dow Jones index

When was Cullinan Oncology the previous earnings report?

No data

When does Cullinan Oncology earnings report?

The next expected earnings date for Cullinan Oncology is 14 March 2025